A
Astellas Pharma US
Sustainability Report and Carbon Intensity Rankings
Is Astellas Pharma US doing their part?
Their DitchCarbon score is 74
Astellas Pharma US has a DitchCarbon Score of 74, indicating a relatively high level of sustainability in their operations. This score reflects the company’s commitment to reducing its carbon intensity. A score closer to 100 suggests that Astellas Pharma US is actively working towards lower emissions and more sustainable practices.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Astellas Pharma US operates in the industrial manufacturing sector, which has a very low carbon intensity ranking. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
Astellas Pharma US operates in Japan, a region with a low carbon intensity rating. This favorable environmental context supports the company’s sustainability efforts by reducing its overall carbon footprint.
Unlock 30+ emissions data points on Astellas Pharma US
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Astellas Pharma US
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
32.71%
...this company is doing 32.71% better in emissions than the industry average.
Astellas Pharma US, Inc., headquartered in Northbrook, Illinois, operates in the pharmaceutical industry and was established in 2005. The company is the U.S. affiliate of Tokyo-based Astellas Pharma Inc., and it specializes in the development and distribution of innovative pharmaceutical products, particularly in the fields of transplantation, urology, and oncology. Astellas Pharma US is committed to improving health worldwide while upholding social responsibility within the community and its collaborative partnerships.
emission intelligence's platform recommendations for Astellas Pharma US
Astellas Pharma US should foster supplier engagement initiatives to promote the reduction of emissions, potentially decreasing their Scope 3 emissions by 35%.
Good news, Astellas Pharma US has embraced SBTi commitments
Astellas Pharma US has established Science Based Targets initiative (SBTi) commitments to significantly reduce their greenhouse gas emissions from company operations, which include both direct emissions and indirect emissions from purchased energy. These targets align with the ambitious goal of limiting global temperature rise to 1.5°C, reflecting the company’s dedication to contributing to climate action.
Participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.